Medical treatment from licensed providers is provided by OpenLoop Healthcare Partners P.C., and it’s affiliated professional entities which are independent medical groups with a network of United States based health care providers.  To learn more, click here.

The trademarks, service marks, trade names, and products referenced on this site (including Wegovy®, Ozempic®, Mounjaro®, and Zepbound™) are the property of their respective owners. VivioMD is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Personalized compounded medications available through the VivioMD program are not manufactured by, or under the direction or control of, Novo Nordisk or Eli Lilly. Only Novo Nordisk has FDA-approved products containing semaglutide, under the trade names Wegovy® and Ozempic®. Novo Nordisk does not sell semaglutide to any entities for use in compounding. Ozempic® is not FDA-approved for weight loss. Only Eli Lilly has FDA-approved products containing tirzepatide, under the trade names Mounjaro® and Zepbound™. Eli Lilly does not sell tirzepatide to any entities for use in compounding. Mounjaro® is not FDA-approved for weight loss

* IIndividual results vary. In the STEP-1 trial (68 weeks), adults without diabetes treated with semaglutide 2.4 mg lost an average of ~15% of body weight versus ~2.4% with placebo, alongside reduced-calorie diet and increased physical activity. Only Novo Nordisk has FDA-approved products containing semaglutide (Wegovy®, Ozempic®, Rybelsus®). Ozempic® is not FDA-approved for weight loss. *Individual results vary. In the SURMOUNT-1 trial (72 weeks), adults without diabetes treated with tirzepatide lost an average of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) of body weight versus 3.1% with placebo, when combined with reduced-calorie diet and increased physical activity. Tirzepatide is FDA-approved for type 2 diabetes and chronic weight management under the trade names Mounjaro® and Zepbound™

Important Safety information: GLP-1 medications are used to treat obesity or overweight (with weight-related problems), along with diet and exercise. GLP-1 medications may have serious side effects, including possible thyroid tumors.  Do not use GLP-1s if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It’s important to share your entire medical history with your provider. Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm. Please visit the medication safety information

In certain situations, where clinically appropriate, a provider may prescribe compounded medication, which is prepared by a state-licensed sterile compounding pharmacy partner. Although compounded drugs are permitted to be prescribed under federal law, they are not FDA-approved as safe or effective and do not undergo FDA review for safety, effectiveness, or manufacturing quality.